Navigation Links
Cerulean Pharma to Present Data on CRLX101's HIF-1a Inhibition at the American Association for Cancer Research Annual Meeting
Date:4/4/2013

CAMBRIDGE, Mass., April 4, 2013 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that researchers will present both pre-clinical and clinical data on Cerulean's Phase 2 candidate, CRLX101, in sessions at the American Association for Cancer Research (AACR) Annual Meeting. Among the findings, Cerulean will share clinical data from a study evaluating synergy between CRLX101 and Avastin® (bevacizumab).

(Logo:  http://photos.prnewswire.com/prnh/20130107/NE37515LOGO )

In multiple animal models, CRLX101 inhibits hypoxia-inducible factor 1a (HIF-1a), which is involved in cancer survival mechanisms, and which is up-regulated in the hypoxic conditions created by anti-angiogenic drugs. Animal models suggest that CRLX101 is synergistic with multiple anti-angiogenic drugs, and this hypothesis is being tested in a clinical trial combining CRLX101 with Avastin, the leading anti-angiogenic medicine.

Dr. Stephen M. Keefe , the Ann B. Young Assistant Professor in Cancer Research at the Perelman School of Medicine at the University of Pennsylvania, will present a poster entitled A Phase Ib-2a Study Evaluating the Nanopharmaceutical CRLX101 in Combination with Bevacizumab (April 9, 8:00 am – 12:00 pm) on a clinical trial studying synergy between CRLX101 and Avastin when combined to treat patients with advanced renal cell carcinoma. Dr. Keefe, who practices at the Abramson Cancer Center of the University of Pennsylvania, will present data showing that the CRLX101-Avastin combination has been well tolerated in six patients treated to date with no dose limiting toxicities observed. Additional patients are being enrolled in the study to confirm combinability and to assess efficacy.

"The pre-clinical data for CRLX101 in combination with anti-angiogenic agents are very impressive. I am excited that we can bring this combination hypothesis into the clinic, and I am encouraged by the results of this trial to date," said Dr. Keefe. "CRLX101's favorable safety profile is encouraging, and its ability to provide durable inhibition of HIF-1a could increase the benefit that anti-angiogenic agents provide to patients."

In addition, Cerulean scientists will participate in the following sessions at AACR:

  • CRLX101, a nanopharmaceutical in phase 2 clinical trials, is synergistic with antiangiogenic treatment through HIF-1a inhibition in an ovarian cancer xenograft model (April 7, 1:00 – 5:00 pm): Douglas Lazarus , director of biology at Cerulean, will present a poster on the improved efficacy of antiangiogenic drugs when combined with CRLX101.
  • Nanotechnology Approaches to the Treatment of Cancer (April 7, 1:00 – 3:00 pm): Dr. Scott D. Eliasof , vice president of research at Cerulean, will participate in a panel discussion led by Mark Davis of the California Institute of Technology on the advantages of using nanoparticles such as CRLX101 for the treatment of cancer, including how nanotechnology enabled the creation of the first clinically relevant HIF-1a inhibitor.

About CRLX101

CRLX101 is an investigational anti-cancer agent that is a dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1α. CRLX101 is a dynamically tumor-targeted nanopharmaceutical designed to concentrate in tumors and release its payload, camptothecin, over an extended period of time, prolonging drug exposure at the site of action. Anti-tumor activity has been observed across a wide range of cancers in animal models and in seven clinical trials. CRLX101 is currently in Phase 2 clinical development. More information on CRLX101 clinical studies can be found at www.clinicaltrials.gov.

About Cerulean Pharma Inc.

Cerulean Pharma Inc. is a clinical-stage company specializing in the development of dynamically tumor-targeted nanopharmaceuticals. Cerulean is applying its proprietary nanopharmaceutical platform to advance a new class of therapeutic agents to address significant unmet medical needs. With an initial focus in oncology, the Company's technology platform can be applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, Bessemer Venture Partners, and CVF, LLC. Cerulean is located in Cambridge, Massachusetts. For more information, please visit the Company's website at http://www.ceruleanrx.com.

Media Contacts:
Kristin Villiotte or Kim McCrossen
Schwartz MSL
cerulean@schwartzmsl.com
+1 781-684-0770


'/>"/>
SOURCE Cerulean Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cerulean Pharmas Lead Candidate Selected as a "Top 10 Oncology Project to Watch"
2. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
3. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
4. Valeant Pharmaceuticals Provides Update to Recent Event
5. X-BODY Announces Multi-Million Dollar Development Alliance With Jiangsu Hengrui Medicine Co., Ltd., A Leading Pharmaceutical Company In China, To Develop Novel Therapeutic Antibodies For AMD
6. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
7. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
8. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
9. Collegium Pharmaceutical Names Douglas Carlson to Vice President of Business Development
10. Kentucky Health Cooperative To Partner With ProCare Rx For Pharmacy Benefit Management
11. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
(Date:5/25/2016)... 25, 2016 According to market ... Growth and Demand Forecast to 2022 - Industry Insights ... Others)" published by P&S Market Research, the global insulin ... 2015, and it is expected to grow at a ... insulin pump segment is expected to witness the fastest ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on ... presentation entitled "High doses of biotin in progressive multiple sclerosis: ... by Professor Ayman Tourbah , Principal Investigator of the ... Academy of Neurology (EAN) in Copenhagen, Denmark ... take place on Sunday, 29 May 2016 from 14:45 to ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... The Georgia State University College of Law ... Atlanta Urban Design Commission. , The annual award recognizes projects, programs, individuals and organizations ... the preservation of its physical heritage and the balance between the old and the ...
(Date:5/25/2016)... The Netherlands (PRWEB) , ... May 25, 2016 , ... ... unprecedented freedom of movement to motion capture, all by utilizing a common Wi-Fi network ... allows users to transmit data from any location with Wi-Fi, and use a mobile ...
(Date:5/25/2016)... ... , ... One Florida-based plastic surgeon’s enthusiasm is proving to be contagious among ... May 13th on Vanity Fair. In fact, as the article explains, more than a ... more than 800,000 Snapchat fans. Commenting on this trend, Dr. Michael Salzhauer, also known ...
(Date:5/25/2016)... ... 2016 , ... The Bank of America Charitable Foundation has awarded a grant ... a pathway to employment and successful careers in healthcare. On Wednesday, May 4th, Rick ... and CEO of Medisend, parent organization and home of the General Myers Veterans Program. ...
(Date:5/25/2016)... ... May 25, 2016 , ... New studies published today by ... across 15 states. The outcomes examined in these studies include recovery of physical ... satisfaction with medical care. , “The goal of the studies is to provide ...
Breaking Medicine News(10 mins):